Filed in archive
Drugs, Vaccines and Therapeutics
by ruth on October 25, 2007
Mayo Clinic has reported positive preliminary results in the Phase 11 clinical trials of a new combination therapy using flavopiridol (an investigational anti-cancer agent that also boosts the effects of other therapeutics including cisplatin) with cisplatin (a platinum compound) for women with platinum-resistant ovarian or primary peritoneal (lining of the abdominal cavity) cancers.
The researchers are now planning on expanding the trial to verify the results. Read more from the Mayo Clinic report.
Of the 18 patients, all of whom were receiving the therapy as a second-line treatment after disease progression, one patient experienced complete response (all signs of cancer gone) and five other patients experienced partial responses (tumor regression). The 33 percent overall response rate (6 of 18 patients) is about twice as high as seen using traditional chemotherapy regimens.
The researchers also offered the combination therapy to five patients with platinum-sensitive (original therapy resulted in no recurrence for greater than 12 months) ovarian cancer. Of these women, one experienced complete response and three others partial response.
The researchers are now planning on expanding the trial to verify the results. Read more from the Mayo Clinic report.
Permalink: Flavopiridol and Cisplatin Combination May Be Effective Against Platinum-Resistant Ovarian Cancer
Tags:
cancer
ovarian+cancer
ovary+cancer
chemotherapy
cisplatin
flavopiridol
biotech
platinum+resistant
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/98698
Mr Wong
Vote for Flavopiridol and Cisplatin Combination May Be Effective Against Platinum-Resistant Ovarian Cancer:
|
Rating: 7.25 out of 4 vote(s) cast.
|
Subscribe
Use the search to look for other interesting posts
| RSS | See all blog subscribe options |
|
What is RSS? | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
| Newsletter | |
| Follow us on Twitter! |








